EP0567201A2 — Vehicles for oral administration of a specific pharmaceutically active acid labile substance
Assigned to AstraZeneca AB · Expires 1993-10-27 · 33y expired
What this patent protects
Improvements in the vehicles for oral administration of pharmaceutically active acid labile substances prone to discolouration, containing omeprazole where the administration vehicle comprises a core containing the omeprazole together with an alkaline reacting compound or an alka…
USPTO Abstract
Improvements in the vehicles for oral administration of pharmaceutically active acid labile substances prone to discolouration, containing omeprazole where the administration vehicle comprises a core containing the omeprazole together with an alkaline reacting compound or an alkaline salt of omeprazole optionally mixed with an alkaline reacting compound, adopting the form either of a number of small beads optionally forming a tablet or a tablet as such and comprising a coating made out of one or more inert reacting subcoating layers comprising tablet excipients which are soluble or rapidly disintegrating in water, or polymeric, water soluble, filmforming compounds, optionally containing pH-buffering, alkaline compounds between the alkaline reacting core and an enteric outer coating layer.
Drugs covered by this patent
- Prilosec (omeprazole) · AstraZeneca (originally Astra AB)
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.